Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology

PurposeAimed to identify the anti-uterine corpus endometrial carcinoma (UCEC) function and characterize the mechanism of quercetin in the treatment of patients infected with COVID-19 via integrated in silico analysis.MethodsThe Cancer Genome Atlas and Genotype Tissue Expression databases were applie...

Full description

Bibliographic Details
Main Authors: Kehan Li, Hejing Liu, Yibin Lin, Liang Gu, Xinli Xiang, Xueqiong Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1151434/full
_version_ 1811158366776459264
author Kehan Li
Hejing Liu
Yibin Lin
Liang Gu
Xinli Xiang
Xueqiong Zhu
Xueqiong Zhu
author_facet Kehan Li
Hejing Liu
Yibin Lin
Liang Gu
Xinli Xiang
Xueqiong Zhu
Xueqiong Zhu
author_sort Kehan Li
collection DOAJ
description PurposeAimed to identify the anti-uterine corpus endometrial carcinoma (UCEC) function and characterize the mechanism of quercetin in the treatment of patients infected with COVID-19 via integrated in silico analysis.MethodsThe Cancer Genome Atlas and Genotype Tissue Expression databases were applied to obtain differentially expressed genes of UCEC and non-tumor tissue. Several in silico methods such as network pharmacology, functional enrichment analysis, Cox regression analyses, somatic mutation analysis, immune infiltration and molecular docking were used to investigate and analysis the biological targets, functions and mechanisms of anti-UCEC/COVID-19 of quercetin. Multiple methods such as CCK8 assay, Transwell assay and western blotting were performed to test proliferation, migration, and protein level of UCEC (HEC-1 and Ishikawa) cells.ResultsFunctional analysis disclosed that quercetin against UCEC/COVID-19 mainly by ‘biological regulation’, ‘response to stimulus’, and ‘regulation of cellular process’. Then, regression analyses indicated that 9 prognostic genes (including ANPEP, OAS1, SCGB1A1, HLA‐A, NPPB, FGB, CCL2, TLR4, and SERPINE1) might play important roles in quercetin for treating UCEC/COVID-19. Molecular docking analysis revealed that the protein products of 9 prognostic genes were the important anti-UCEC/COVID-19 biological targets of quercetin. Meanwhile, the proliferation and migration of UCEC cells were inhibited by quercetin. Moreover, after treatment with quercetin, the protein level of ubiquitination-related gene ISG15 was decreased in UCEC cells in vitro.ConclusionsTaken together, this study provides new treatment option for UCEC patients infected with COVID-19. Quercetin may work by reducing the expression of ISG15 and participating in ubiquitination-related pathways.
first_indexed 2024-04-10T05:22:13Z
format Article
id doaj.art-3f9ba530be1547dea1ea98bfa3ceb6c2
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-04-10T05:22:13Z
publishDate 2023-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-3f9ba530be1547dea1ea98bfa3ceb6c22023-03-08T06:20:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11514341151434Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacologyKehan Li0Hejing Liu1Yibin Lin2Liang Gu3Xinli Xiang4Xueqiong Zhu5Xueqiong Zhu6Center of Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaCenter of Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaCenter of Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaDepartment of Obstetrics and Gynecology, Taizhou Women and Children’s Hospital of Wenzhou Medical University, Taizhou, Zhejiang, ChinaCenter of Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaCenter of Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaDepartment of Obstetrics and Gynecology, Taizhou Women and Children’s Hospital of Wenzhou Medical University, Taizhou, Zhejiang, ChinaPurposeAimed to identify the anti-uterine corpus endometrial carcinoma (UCEC) function and characterize the mechanism of quercetin in the treatment of patients infected with COVID-19 via integrated in silico analysis.MethodsThe Cancer Genome Atlas and Genotype Tissue Expression databases were applied to obtain differentially expressed genes of UCEC and non-tumor tissue. Several in silico methods such as network pharmacology, functional enrichment analysis, Cox regression analyses, somatic mutation analysis, immune infiltration and molecular docking were used to investigate and analysis the biological targets, functions and mechanisms of anti-UCEC/COVID-19 of quercetin. Multiple methods such as CCK8 assay, Transwell assay and western blotting were performed to test proliferation, migration, and protein level of UCEC (HEC-1 and Ishikawa) cells.ResultsFunctional analysis disclosed that quercetin against UCEC/COVID-19 mainly by ‘biological regulation’, ‘response to stimulus’, and ‘regulation of cellular process’. Then, regression analyses indicated that 9 prognostic genes (including ANPEP, OAS1, SCGB1A1, HLA‐A, NPPB, FGB, CCL2, TLR4, and SERPINE1) might play important roles in quercetin for treating UCEC/COVID-19. Molecular docking analysis revealed that the protein products of 9 prognostic genes were the important anti-UCEC/COVID-19 biological targets of quercetin. Meanwhile, the proliferation and migration of UCEC cells were inhibited by quercetin. Moreover, after treatment with quercetin, the protein level of ubiquitination-related gene ISG15 was decreased in UCEC cells in vitro.ConclusionsTaken together, this study provides new treatment option for UCEC patients infected with COVID-19. Quercetin may work by reducing the expression of ISG15 and participating in ubiquitination-related pathways.https://www.frontiersin.org/articles/10.3389/fonc.2023.1151434/fullCOVID-19uterine corpus endometrial carcinoma (UCEC)quercetinubiquitinationnetwork pharmacology (NP)
spellingShingle Kehan Li
Hejing Liu
Yibin Lin
Liang Gu
Xinli Xiang
Xueqiong Zhu
Xueqiong Zhu
Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
Frontiers in Oncology
COVID-19
uterine corpus endometrial carcinoma (UCEC)
quercetin
ubiquitination
network pharmacology (NP)
title Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
title_full Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
title_fullStr Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
title_full_unstemmed Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
title_short Discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with COVID-19 through network pharmacology
title_sort discovery of therapeutic targets of quercetin for endometrial carcinoma patients infected with covid 19 through network pharmacology
topic COVID-19
uterine corpus endometrial carcinoma (UCEC)
quercetin
ubiquitination
network pharmacology (NP)
url https://www.frontiersin.org/articles/10.3389/fonc.2023.1151434/full
work_keys_str_mv AT kehanli discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT hejingliu discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT yibinlin discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT lianggu discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT xinlixiang discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT xueqiongzhu discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology
AT xueqiongzhu discoveryoftherapeutictargetsofquercetinforendometrialcarcinomapatientsinfectedwithcovid19throughnetworkpharmacology